These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
46. Assessment of the relative therapeutic effects of vaccines on virus load and immune responses in small groups at several time points: efficacy of mucosal and subcutaneous polypeptide vaccines in rhesus macaques exposed to SHIV. Kuznetsov VA; Stepanov VS; Berzofsky JA; Belyakov IM J Clin Virol; 2004 Dec; 31 Suppl 1():S69-82. PubMed ID: 15567097 [TBL] [Abstract][Full Text] [Related]
47. CAF01 liposomes as a mucosal vaccine adjuvant: In vitro and in vivo investigations. Christensen D; Foged C; Rosenkrands I; Lundberg CV; Andersen P; Agger EM; Nielsen HM Int J Pharm; 2010 May; 390(1):19-24. PubMed ID: 19879346 [TBL] [Abstract][Full Text] [Related]
48. Mucosal immunization: a review of strategies and challenges. Patel H; Yewale C; Rathi MN; Misra A Crit Rev Ther Drug Carrier Syst; 2014; 31(4):273-303. PubMed ID: 25072196 [TBL] [Abstract][Full Text] [Related]
49. Development of oral microencapsulated forms for delivering viral vaccines. Nechaeva E Expert Rev Vaccines; 2002 Oct; 1(3):385-97. PubMed ID: 12901577 [TBL] [Abstract][Full Text] [Related]
50. Mucosal vaccines and technology. Miquel-Clopés A; Bentley EG; Stewart JP; Carding SR Clin Exp Immunol; 2019 May; 196(2):205-214. PubMed ID: 30963541 [TBL] [Abstract][Full Text] [Related]
52. [Recent progress for the development of mucosal vaccine]. Nochi T; Kiyono H Tanpakushitsu Kakusan Koso; 2009 Jun; 54(8 Suppl):1089-95. PubMed ID: 21089546 [No Abstract] [Full Text] [Related]
53. [Strategic dominance of the mucosal immune system in the defence and tolerance]. Mestecký J; Raska M Cas Lek Cesk; 2011; 150(9):480-8. PubMed ID: 22132615 [TBL] [Abstract][Full Text] [Related]
54. New advances in mucosal vaccination. Ranasinghe C Immunol Lett; 2014 Oct; 161(2):204-6. PubMed ID: 24462961 [TBL] [Abstract][Full Text] [Related]
55. Mucosal delivery routes for optimal immunization: targeting immunity to the right tissues. Czerkinsky C; Holmgren J Curr Top Microbiol Immunol; 2012; 354():1-18. PubMed ID: 21053117 [TBL] [Abstract][Full Text] [Related]
56. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA. Holmgren J; Adamsson J; Anjuère F; Clemens J; Czerkinsky C; Eriksson K; Flach CF; George-Chandy A; Harandi AM; Lebens M; Lehner T; Lindblad M; Nygren E; Raghavan S; Sanchez J; Stanford M; Sun JB; Svennerholm AM; Tengvall S Immunol Lett; 2005 Mar; 97(2):181-8. PubMed ID: 15752556 [TBL] [Abstract][Full Text] [Related]
57. [The development of mucosal vaccine using bacterial function for targeting mucosal tissues]. Suzuki H; Kondoh M; Yagi K; Kiyono H; Kunisawa J Yakugaku Zasshi; 2014; 134(5):629-34. PubMed ID: 24790045 [TBL] [Abstract][Full Text] [Related]